文献速递消化道肿瘤放疗放疗物理与技术

Osalmid作为新型RRM2抑制剂增强食管癌放射敏感性

Osalmid, a Novel Identified RRM2 Inhibitor, Enhances Radiosensitivity of Esophageal Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-08-04

该研究探讨RRM2在食管癌放射抵抗中的作用及Osalmid的增敏效果。结果显示RRM2在治疗抵抗食管癌组织中高表达且与总生存期缩短相关,Osalmid抑制ERK1/2通路并增强电离辐射诱导的DNA损伤、凋亡和衰老,体内外均与放疗协同抑瘤且未增加毒性。

要点

  • RRM2在治疗抵抗食管癌中高表达,强染色与总生存期缩短相关
  • Osalmid抑制ERK1/2通路,增强电离辐射诱导的DNA损伤、凋亡和衰老
  • Osalmid联合放疗在移植瘤模型中协同抑瘤,未增加血液和脏器毒性

核心结论

  • RRM2在食管癌放射抵抗中起重要作用,Osalmid与电离辐射协同发挥体内外抗肿瘤效应。

研究设计与样本

  • 基础研究:免疫组化检测食管癌组织RRM2表达,体外用四唑盐、集落形成和流式细胞术评估Osalmid对增殖、凋亡和细胞周期的影响,并用免疫荧光、流式、Western blot和β-半乳糖苷酶染色检测DNA损伤、凋亡和衰老,体内采用食管癌移植瘤小鼠模型。

主要发现

  • 治疗抵抗食管癌组织中RRM2表达远高于治疗敏感组织,RRM2强染色与较短总生存期相关。
  • Osalmid对食管癌细胞有直接细胞毒性,并抑制ERK1/2信号通路。
  • Osalmid显著增强电离辐射诱导的DNA损伤、凋亡和衰老。
  • Osalmid联合电离辐射显著抑制移植瘤生长,且未增加血液系统和内脏毒性。

临床怎么用

  • RRM2高表达或治疗抵抗的食管癌患者可能从Osalmid联合放疗中获益,但需临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Esophageal cancer (EC) is an aggressive malignancy and is often resistant to currently available therapies. Inhibition of ribonucleotide reductase small subunit M2 (RRM2) in tumors is speculated to mediate chemosensitization. Previous studies have reported that Osalmid could act as an RRM2 inhibitor. We explored whether RRM2 was involved in radioresistance and the antitumor effects of Osalmid in EC. METHODS AND MATERIALS: RRM2 expression was detected by immunohistochemistry in EC tissues. The effects of Osalmid on cell proliferation, apoptosis, and cell cycle were assessed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphhenyl tetrazolium, colony formation, and flow cytometry assays. DNA damage, cell apoptosis, and senescence induced by Osalmid or ionizing radiation (IR) alone, or both, were detected with immunofluorescence, flow cytometry, Western blot, and β-galactosidase staining. A xenograft mouse model of EC was used to investigate the potential synergistic effects of Osalmid and IR in vivo. RESULTS: The expression of RRM2 in treatment-resistant EC tissues is much higher than in treatment-sensitive EC, and strong staining of RRM2 was correlated with shorter overall survival. We observed direct cytotoxicity of Osalmid in EC cells. Osalmid also produced inhibition of the ERK1/2 signal transduction pathway and substantially enhanced IR-induced DNA damage, apoptosis, and senescence. Furthermore, treatment with Osalmid and IR significantly suppressed tumor growth in xenograft EC models without additional toxicity to the hematologic system and internal organs. CONCLUSIONS: Our study revealed that RRM2 played a vital role in radioresistance in EC, and Osalmid synergized with IR to exert its antitumor effects both in vitro and in vivo.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Tang Q, Wu L, Xu M, et al. Osalmid, a Novel Identified RRM2 Inhibitor, Enhances Radiosensitivity of Esophageal Cancer. Int J Radiat Oncol Biol Phys. 2020. PMID: 32763454. doi:10.1016/j.ijrobp.2020.07.2322

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。